Latest News
Immunome, Inc.
- Immunome, Inc. Estimates – NASDAQ:IMNM
- Immunome Stock Gets A Boost In Visibility After William Blair Starts Outperform Coverage
- William Blair initiates Immunome stock coverage with outperform rating By Investing.com
- Immunome's Varegacestat: Could It Become The Second FDA-Approved Desmoid Tumor Treatment?
- Immunome (IMNM) Stock Dropped, What Is Behind The Latest Attention?
- Immunome stock holds at Stifel as Bristol deal cleans up license
- Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
- Immunome (IMNM) Stock May Be A Bargain After IM 1340 Clearance
- Stifel initiates Immunome stock coverage with Hold rating at $24
- Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
- Immunome gains FDA IND clearance for IM‑1340 solid tumour study
- Immunome receives FDA clearance for IM-1340 solid tumor trial By Investing.com
Headlines from the last 30 days, linking to the original publishers. See all market news →